Consensus conference on the management of tumor lysis syndrome

Patrizia Tosi, Giovanni Barosi, Carlo Lazzaro, Vincenzo Liso, Monia Marchetti, Enrica Morra, Andrea Pession, Giovanni Rosti, Antonio Santoro, Pier Luigi Zinzani, Sante Tura

Research output: Contribution to journalArticlepeer-review

Abstract

Tumor lysis syndrome is a potentially life threatening complication of massive cellular lysis in cancers. Identification of high-risk patients and early recognition of the syndrome is crucial in the institution of appropriate treatments. Drugs that act on the metabolic pathway of uric acid to allantoin, like allopurinol or rasburicase, are effective for prophylaxis and treatment of tumor lysis syndrome. Sound recommendations should regulate diagnosis and drug application in the clinical setting. The current article reports the recommendations on the management of tumor lysis syndrome that were issued during a Consensus Conference project, and which were endorsed by the Italian Society of Hematology (SIE), the Italian Association of Pediatric Oncologists (AIEOP) and the Italian Society of Medical Oncology (AIOM). Current concepts on the pathophysiology, clinical features, and therapy of tumor lysis syndrome were evaluated by a Panel of 8 experts. A consensus was then developed for statements regarding key questions on tumor lysis syndrome management selected according to the criterion of relevance by group discussion. Hydration and rasburicase should be administered to adult cancer patients who are candidates for tumor-specific therapy and who carry a high risk of tumor lysis syndrome. Cancer patients with a low-risk of tumor lysis syndrome should instead receive hydration along with oral allopurinol. Hydration and rasburicase should also be administered to patients with clinical tumor lysis syndrome and to adults and high-risk children who develop laboratory tumor lysis syndrome. In conclusion, the Panel recommended rasburicase for tumor lysis syndrome prophylaxis in selected patients based on the drug efficacy profile. Methodologically rigorous studies are needed to clarify its cost-effectiveness profile.

Original languageEnglish
Pages (from-to)1877-1885
Number of pages9
JournalHaematologica
Volume93
Issue number12
DOIs
Publication statusPublished - Dec 2008

Keywords

  • Lymphoma
  • Rasburicase
  • Tumor lysis syndrome

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Consensus conference on the management of tumor lysis syndrome'. Together they form a unique fingerprint.

Cite this